Rik Ossenkoppele
31 – 40 of 193
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Hemispheric asymmetry of tau pathology is related to asymmetric amyloid deposition in Alzheimer's Disease
- Contribution to journal › Article
-
Mark
Treatment-related amyloid clearance (TRAC) : a framework to characterize patients in the era of anti-amyloid therapies
- Contribution to journal › Debate/Note/Editorial
-
Mark
Complementary utility of plasma biomarkers and Aβ-PET for diagnosis, risk-stratification, and treatment monitoring in Alzheimer's disease
- Contribution to journal › Debate/Note/Editorial
- 2024
-
Mark
Combined Connectomics, MAPT Gene Expression, and Amyloid Deposition to Explain Regional Tau Deposition in Alzheimer Disease
- Contribution to journal › Article
-
Mark
Plasma Biomarker Strategy for Selecting Patients with Alzheimer Disease for Antiamyloid Immunotherapies
- Contribution to journal › Article
-
Mark
The implications of amyloid-β pathology : only time will tell
- Contribution to journal › Article
-
Mark
Personal social network strengthens adherence to lifestyle changes in individuals with subjective cognitive decline
- Contribution to journal › Article
-
Mark
Survey among experts on the future role of tau-PET in clinical practice and trials
- Contribution to journal › Article
-
Mark
Cognitively defined Alzheimer's dementia subgroups have distinct atrophy patterns
- Contribution to journal › Article
-
Mark
Fluid Biomarker Changes After Amyloid-β–Targeting Drugs
- Contribution to journal › Debate/Note/Editorial
